Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT03750669
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
- NCT03750669 ↗
- Completed
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Focused
We haven't built an HCP commentary report on NCT03750669 (AG regimen and mFolfirinox in Pancreatic Adenocarcinoma Resectable) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on NCT03750669 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Sequential Use of Nab-paclitaxel Plus Gemcitabine and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer: A Randomized Control Study
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy
- Interventions
- AG regimen; mFolfirinox
- Arms
- Neoadjuvant Chemotherapy · Experimental
- control · No intervention
- Enrollment
- 324
- Primary outcomes
- event-free survival (EFS)
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Start
- Oct 20, 2018
- Primary completion
- Nov 1, 2024
- Results posted
- No
- Registry record
- NCT03750669 · updated May 13, 2025